Project Grant K23AI193246
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $183K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This $3,304,164 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to determine the real-world comparative effectiveness, cost-effectiveness, safety, and impact of the recently approved maternal respiratory syncytial virus (RSV) vaccine and extended-half-life monoclonal antibody products in reducing RSV-associated respiratory morbidities in infants and...
- This $402,731 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), authorized under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a program to increase the number of next-generation physician-scientists who can apply knowledge of microbiology, immunology, and research techniques to improve reproductive, maternal, and child health. The award will support 4 physician-scientists in pediatrics or obstetrics/gynecology residency...
- This $680,562 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the long-term lung epithelial alterations resulting from early-life respiratory syncytial virus (RSV) infection. The research aims to determine the mechanisms by which early-life RSV infection predisposes individuals to developing asthma later in life, focusing on the role of innate cytokines like IL-1β and IL-33 in driving...
- This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The grant aims to develop two innovative vaccine candidates to prevent pulmonary nontuberculous mycobacterial (NTM) infections, which have surpassed tuberculosis as a global health concern. The research involves screening 13 vaccine...
- This Project Grant award of $781,129 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a 5-year study to validate and extend an integrated host-microbe (IHM) diagnostic approach for accurately diagnosing lower respiratory tract infections (LRTIs) in critically ill children. The study aims to: 1) validate the performance of the existing IHM LRTI diagnostic classifier, 2) develop a novel host gene expression...
- This $779,170 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to determine the burden of rhinoviruses (RVs) as a cause of severe respiratory illnesses leading to hospitalization in children. The 5-year study, starting on August 15, 2025, will create a longitudinal cohort of children in Madison, Wisconsin to identify circulating RVs and establish a nasal transcriptome to differentiate clinical RV...
- This federal Project Grant award of $545,563.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a study on the "Real-World Effectiveness of Maternal RSV Vaccination". The grant aims to evaluate the effectiveness of the world's first licensed RSV vaccine when administered to pregnant women between 32-36 weeks gestation, in preventing RSV-associated lower respiratory tract...
- This Project Grant award of $364,484, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel bronchodilators to alleviate respiratory distress in young children infected with Respiratory Syncytial Virus (RSV). The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will screen 8 clinically relevant soluble guanylate cyclase (SGC)...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $152,097 to The University of Texas MD Anderson Cancer Center to conduct research on influenza- and respiratory syncytial virus-associated pulmonary aspergillosis (IAPA/RSV-APA), which are deadly secondary mold infections in immunocompromised patients. The research aims to characterize the post-viral impairment of anti-Aspergillus immune...